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Abstract
Since their discovery in patients with autosomal dominant (AD) chronic mucocutaneous candidiasis (CMC) in 2011, heterozygous STAT1 gain-of-function (GOF) mutations have increasingly been identified worldwide. The clinical spectrum associated with them needed to be delineated. We enrolled 274 patients from 167 kindreds originating from 40 countries from five continents. Demographic data, clinical features, immunological parameters, treatment, and outcome were recorded. The median age of the 274 patients was 22 years (range: 1 -71 years); 98% of them had CMC, with a median age at onset of one year (range: 0 -24 years). Patients often displayed bacterial (74%) infections, mostly due to Staphylococcus aureus (36%), including the respiratory tract and the skin in 47% and 28% of patients, respectively, and viral (38%) infections, mostly due to Herpesviridae (83%) and affecting the skin in 32% of patients. Invasive fungal infections (10%), mostly caused by Candida spp. (29%), and mycobacterial disease (6%) caused by Mycobacterium tuberculosis, environmental mycobacteria, or BCG vaccines, were less common. Many patients had autoimmune manifestations (37%), including hypothyroidism (22%), type 1 diabetes (4%), blood cytopenia (4%), and systemic lupus erythematosus (2%). Invasive infections (25%), cerebral aneurysms (6%), and cancers (6%) were the strongest predictors of poor outcome. CMC persisted in 39% of the 202 patients receiving prolonged antifungal treatment. Circulating IL-17A-producing T-cell count was low for most (82%) but not all of the patients tested. STAT1 GOF mutations underlie AD CMC, as well as an unexpectedly wide range of other clinical features, including not only a variety of infectious and autoimmune diseases, but also cerebral aneurysms and carcinomas that confer a poor prognosis.
Introduction
Chronic mucocutaneous candidiasis (CMC), characterized by persistent or recurrent infections of the nails, skin, oral or genital mucosae with Candida spp, mainly C. albicans, may result from primary immunodeficiencies (PIDs). 1 In patients with T-cell deficiencies, CMC is associated with various infections and autoimmune diseases. 1 CMC is one of the most common infections in patients with autosomal dominant (AD) hyper-IgE syndrome (AD-HIES) 2 and the only infectious complication reported in patients with autosomal recessive (AR) autoimmune polyendocrine syndrome type I (APS-I). 3 By contrast, since the late 1960s, patients have been reported who display an apparently inherited form of isolated CMC and no distinctive associated clinical or immunological phenotype (CMC disease, CMCD). 1 However, invasive candidiasis, peripheral dermatophytosis, bacterial infections of the skin, and respiratory tract have occasionally been reported in some CMCD patients. 1, 4 Autoimmune diseases, typically affecting the thyroid, have also been described in these patients. 1 CMCD can be life-threatening as it is associated with an unexplained increase in the risk for squamous cell carcinoma 1, 5 and cerebral aneurysm. 1, 6 A number of the CMCD cases reported belonged to multiplex and/or consanguineous families suggestive of AD and AR inheritances. 1 The pathogenesis of CMC, first studied in PIDs with syndromic CMC, strongly suggested a role for IL-17A, IL-17F, and IL-22 in mucocutaneous immunity to C. albicans. 1 Patients with AD HIES, heterozygous for STAT3 loss-of-function mutations, have low proportions of IL-17A, IL-17F, and IL-22-producing T cells ex vivo and in vitro. [7] [8] [9] Patients with AR APS-1 and biallelic loss-of-function (LOF) mutations of AIRE 10 have high plasma titers of neutralizing autoantibodies against IL-17A, IL-17F, and IL-22. 11, 12 Low proportions of circulating IL-17A, IL-17F, and IL-22-producing T cells have also been found in some patients with Mendelian susceptibility to mycobacterial disease (MSMD) and AR IL-12Rβ1 or IL-12p40 deficiency, who may also develop CMC. 8, 13 Patients with AR CARD9 deficiency and various invasive fungal diseases occasionally display CMC and low IL-17A
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Results

Genetic and immunological features
We studied 274 patients from 167 kindreds originating from 40 countries on five continents, most of whom were from Europe (62%) ( Table S1 in the Supplement). M/F ratio was 1.03, and median age of the patients at the time of the study was 22 years (range: 1 -71 years). In total, 167 of the 274 cases (61%) were familial (60 kindreds) (Table S1 ), the remaining 107 cases being sporadic (107 kindreds). Three of the sporadic cases had a relevant familial history of disease previously reported to be associated with CMCD (carcinoma, autoimmunity, or aneurysm) that could not be explored genetically. We identified 76 mutations in STAT1 (Table S1) ; the mutation affected the CCD in 104 kindreds (62%), the DBD in 58 (35%) kindreds, the transactivation domain (TAD) in 2 (1%) kindreds, the N-ter domain (NTD) in 2 (1%) kindreds, and the SH2 domain (SH2D) in one (1%) kindred. All the 76 STAT1 mutations were tested in vitro and were all found to be GOF in each functional assay tested (at least one assay per mutation). 20 
Fungal infections
CMC was observed in 268 (98%) of the 274 individuals carrying STAT1 GOF mutations (Table S2) , with a median age at onset of 1 year (range: birth -24 years) ( Figure 1A ).
None of the six patients without CMC (median age 32 years, range: 4 -61 years) was totally asymptomatic. One had invasive fungal infection, five had invasive bacterial infections, four had hypothyroidism, one had a cerebral aneurysm. Three of them had a familial history of CMC. Mucocutaneous fungal infections mostly affected the oral mucosae (93% of patients, thrush, glossitis, and/or cheilitis) ( Table 2) . Skin (57%, pustules, annular plaques, intertrigo), esophageal/genital (56%), and/or nail (56%, onyxis, perionyxis) infections were also often reported ( Table 2 ). Recurrent and/or severe aphthous stomatitis occurred in 125 (46%) patients, and candidiasis of the scalp occurred in 55 (20%) patients. Candida spp. were isolated from various specimens (skin, nails, throat, genital/esophageal mucosae) (Table 3) , and C. albicans was the species most frequently isolated (95% of the 147 Candida isolates). Superficial dermatophytic infections of the scalp, skin or nails were suspected in 44 (16%) patients and were microbiologically confirmed (Trichophyton spp., Microsporon spp.) in 52% of these patients. Photographs of mucocutaneous fungal infections are found in Figure 2 . Twenty-eight (10%) patients developed invasive fungal infections ( 
Bacterial infections
Bacterial infections were observed in 202 of the 274 patients studied (74%; Table 2 & Table S2 ). LRIs were reported in 129 patients (47%, Table 1 ) with often recurrent lobar pneumonia, bronchitis, and/or interstitial pneumonia. Streptococcus pneumoniae (n=13), Pseudomonas aeruginosa (n=13), Haemophilus influenzae (n=9), and S. aureus (n=7) were the most frequent pathogens (Table 3) . Ear-nose-and-throat (ENT) infections were observed in 121 of the 274 patients (44%), mostly as recurrent or chronic sinusitis or otitis media. Recurrent conjunctivitis/keratitis were observed in 39 patients, and 15 patients had blepharitis or ectropion. Recurrent skin infections were found in 77 patients (28%) ( Table   2 ). Folliculitis was the main skin infection, followed by cellulitis, abscesses, and paronychia. The causative agent was documented in 25% of cutaneous infections, with S. aureus isolated in most cases. Other probable bacterial infections included recurrent pyelonephritis (n=8), severe gastroenteritis (n=8), sepsis (n=7), or bone and joint infections (n=3). Seventeen patients (6%) developed mycobacterial diseases. Lung infections were due to M. tuberculosis (n=3) or non-tuberculous, environmental mycobacteria (n=3). Skin disease and adenitis were caused by Bacille Calmette-Guérin (BCG) vaccine or environmental mycobacteria (n=5), and disseminated disease by BCG (n=2), M. tuberculosis (n=3), or M. genavensae (n=1), Table 3 . Two thirds of the patients were presumed to be vaccinated with BCG during childhood according to the global BCG vaccination policies.
Viral infections
One hundred three patients (of 274, 38%) developed at least one systemic or atypical viral infection, or recurrent mucocutaneous viral infections ( Table 2 & Table S2 ). Recurrent mucocutaneous viral infections (rash, stomatitis, vulvitis or keratitis) affected 88 patients (32%). The main causal agents were Herpes Simplex and Varicella-Zoster viruses (Table   3 ). Eighteen patients (7%) had severe chickenpox (i.e. rash associated with VZV pneumonitis or cutaneous bacterial superinfection), and 33 (12%) had a history of shingles during childhood that was recurrent in 58% of cases. Thirty-two (12%) patients had recurrent Molluscum contagiosum or warts. Severe systemic infections were reported in 23 (8%) of the 274 patients: cytomegalovirus (CMV) and Epstein-Barr virus (EBV) were the viruses most frequently found (Table 3) . Uncontrolled CMV viremia requiring antiviral treatment was observed for 8 patients. Six patients had CMV disease with proven organ infection, including one patient with retinitis, two with ulcerative digestive infections, and three with lung infections, one of whom also had encephalitis. One patient had a combined adenovirus and EBV disseminated infection (blood, lung and gut) requiring rituximab with partial efficacy (P234). Chronic active EBV infections (n=10) were less severe and did not require specific treatment. A few cases of severe HHV-6 and parvovirus (n=4) infection were described, resulting in severe sepsis or hemophagocytosis, and one patient developed BK-virus urinary tract infection with functional consequences. Two patients displayed severe disease due to live virus vaccines (small-pox and measles). Two patients had chronic hepatitis C infection leading to cirrhosis.
Autoimmune and inflammatory diseases
Clinical autoimmunity and/or autoimmune antibodies were documented in 118 (43%) of the 274 patients (Table 4 & Table S3 ). Median age was 24 years in this subpopulation (range: 3.5 years -71 years) at the time of the study, and the M/F sex ratio was 0.79. One hundred one (37%) displayed clinical autoimmune manifestations, which represents a For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From much higher rate than the standard population (~3%), 61 and 19% of these patients had more than one clinical autoimmune disorder. Most of these features were related to thyroid disease: hypothyroidism (n=60) requiring hormone substitution, and hyperthyroidism in one patient; 62% of these patients were women. Some patients displayed other autoimmune endocrine diseases, mainly type 1 diabetes mellitus (n=11). Cutaneous diseases were observed in 28 patients displaying vitiligo, alopecia, or psoriasis. Five female patients displayed systemic lupus erythematosus (SLE) with systemic features (i.e.
vasculitis, serositis or antiphospholipid syndrome with a history of thrombo-embolism), and one patient had scleroderma. A few patients displayed pernicious anemia (n=1) or celiac disease (n=4) with specific autoantibodies (auto-Abs). Autoimmune hepatitis began before adulthood in six patients (67% being men). Hematologic autoimmunity (n=11, 73%
of men) consisted of chronic hemolytic anemia or autoimmune thrombocytopenia during childhood. Two patients had ankylosing spondylitis, and one patient had multiple sclerosis.
Six patients displayed inflammatory bowel disease including Crohn's disease (n=2), enteropathy with lymphocytic infiltration (n=2), and ulcerative colitis (n=2). Auto-Abs were found in 66 of the 157 patients tested (42%). Most patients with clinical autoimmunity tested were found positive for autoantibodies (n=49/75, 65%), mostly for anti-nuclear Abs (n=18), anti-thyroid Abs (n=21), Abs against other endocrine glands (n=7), and gastrointestinal Abs (n=8). Auto-Abs were also detected in the absence of clinical symptoms in 20% of the patients tested (n=17/84), mostly anti-nuclear Abs (76%) and anti-thyroid Abs (18%).
Other clinical features
Aneurysms (n=17/274, 6%; Table 4, Table S3 & Figure 2 ) occurred at a higher rate than the standard population (~3%) 62 and were diagnosed at a median age of 23 years (range: 3 -50 years), which is much younger than the standard population (~50 years). 62 There was no difference between the sexes. Aneurysms tend to be more frequent in patients with underlying autommunity (p=0.05), type I diabetes in particular (27% vs. 5%, p<0.01).
Diagnosis was based on symptoms and radiologically confirmed in 15 patients. Systematic radiologic investigations identified two additional patients. Cerebral imaging was also carried out for 25 other asymptomatic patients and yielded normal results. Fifty-percent of symptomatic patients endured hemorrhages; the others had abdominal pain, and neurological manifestations, such as hemiplegia, seizures or attention lapses. Most aneurysms were located in the cerebral vascular system (82%). Most affected patients had multiple aneurysms in the CNS, mostly in the basilar trunk, vertebral arteries, and cerebral and intracranial carotid arteries. Extracerebral aneurysms were found in the abdominal aorta, iliac arteries, and lung arteries (n=3). Histological and microbiological investigations were performed in one patient (P27 , Table S3 ) and were negative. 44 The other neurological features observed were cerebral vasculitis (n=3), epilepsy (n=3), polyneuropathy (n=1), multiple sclerosis (n=1), and hemiplegia of unknown origin (n=1). Cognitive disability was diagnosed in eight patients during childhood, a frequency slightly higher than that in the general population. 63 Fourteen patients had cutaneous, gastrointestinal, or laryngeal carcinoma, eleven of which were squamous cell carcinomas, one patient had melanoma, and another one acute leukemia, leading to an overall cancer rate of 5.8% (95% confidence interval 3.03%-8.57% ) ( Table 4 ). The M/F ratio was 1.0. We compared this cancer rate to that observed in the reference 2000 US Standard population. 64, 65 To account for the low median age of the STAT1 GOF patients, we computed the expected cancer rate in the reference population as a weighted average of the age-specific cancer rates, in which the weights were the proportions of STAT1 GOF patients in the corresponding age groups. The expected age-adjusted cancer rate in the reference population was found to be 1.1%, below the lower bound of the confidence interval of the rate in the population of patients studied
here. This result supports that STAT1 GOF patients may have an increased risk of cancer.
Carcinoma were more frequent in patients with a history of esophagitis (10% vs. 2%, p=0.002). Two patients had benign tumors of vascular origin. Finally, other diseases, such as asthma, eczema, and signs of allergy were observed in 54 patients (20%), a frequency similar to that found in the general population and without unusual severity.
66
Preventive and curative treatment
Two hundred two (of 274, 74%) patients needed long-term antifungal treatment, mostly systemic ( cotrimoxazole was the main agent used (Table 5) 
Clinical outcome
Thirty-three patients (of 274, 12%) failed to thrive ( Figure 2 ), all with a previous history of recurrent pneumonia or bronchitis, and displaying acute secondary infectious episodes caused by P. aeruginosa (n=11 out of 57, 19%), S. aureus (n=6, 11%), non-tuberculous mycobacteria (n=4, 7%) or Enterobacteriaceae (n=2, 3%). One of these patients also had an associated pneumatocyst, and three other patients underwent lobectomy. Thirty-four patients (of 274, 12%) died ( 
symptomatic aneurysm than those without (87%) any of these three complications ( Figure 1B ). Other causes of death possibly associated with STAT1 GOF phenotypes included fulminant hepatitis (1 patient from an unknown cause, and 1 from autoimmune hepatitis), and complication of HSCT in three patients. Three patients died from unrelated causes, at the ages of 10, 46, and 50 years. Lymphocyte cell subset abnormality (low CD4+ and/or CD19+ lymphocyte counts) was associated with a higher mortality rate (19% vs. 6%, (p=0.004), and 25% vs. 7%, (p<0.001), respectively ).
For
Discussion
We show here that CMC is the most common infectious manifestation in patients carrying STAT1 GOF mutations, and is frequently resistant to azole treatments. Surprisingly, these patients often display viral, bacterial, and other fungal infections. In addition, these patients also develop various types of autoimmunity, as well as aneurysms and carcinomas, much more often than the general population. The presence of these latter complications accounts for a poor outcome. The penetrance of CMC is very high, as only six (2%) STAT1 GOF patients (2.8% excluding all probands) never had CMC at a median age of 32 years.
CMC typically begins in early childhood, although it may first present up to the third decade of life, and signs and symptoms varied within and between families. 20 In these patients, CMC is most likely the consequence of impaired IL-17A and IL-17F immunity, 79 and/or impaired IL-17 immunity, as shown in animal models. 80 Their pathogenesis may also be autoimmune, as in cerebral vasculitis, or infectious, as in systemic Candida infection. 1 Patients with aneurysms did not differ markedly from the others in terms of invasive fungal infection rates (p=0.6), but they seemed to display more autoimmune disorders. Patients with an interferonopathy caused by SAMHD1 mutations also display cerebral vasculitis and aneurysm. 76, 81 The frequency of skin and ENT carcinomas was high, and probably better estimated than that of cerebral aneurysm. These conditions are better understood and probably result, at least in part, from CMC and the chronic muco-cutaneous inflammation (especially esophagitis) it causes. 82 Enhanced IFN production is unlikely to play a direct role, as these cytokines have antitumoral activity. 83 Patients with esophagitis and dysphagia should be regularely screened for tumor by sequential biopsies of the esophagus. Taken together, STAT1 GOF-associated AD CMCD
should not be considered benign and should be handled at centers with experience in the diagnosis and management of such patients.
The heterogeneity of clinical care for the patients in this cohort makes it difficult to issue uniform recommendations concerning optimal management. The high rate of CMC resistance to antifungal treatments is a major issue. Indeed, azole resistance necessitates the intravenous use of alternative antifungals (amphotericin B, echinocandins) that could lead 
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